The 5th edition of the Hanson Wade Bacteriophage Therapy Summit will be held as a Virtual summit from Tuesday 21st February till Thursday 23rd February 2023.
What is the 5th Bacteriophage Therapy Summit and Why attend?
Focusing on the A-Z of phage development, the definitive commercial-orientated conference is focusing on the acceleration of phage-based applications for organizations pioneering with phage pipelines.
The 5th edition of the Bacteriophage Therapy Summit returns as the global industry forum delivering maturing drug development expertise and investment to phage-based therapies, to better understand in-human stability and advance in clinical benefit. For 3 days, over 20 experts speakers from across the globe from a diversity of fields will gather to gain comprehensive and actionable insights into phage-based therapies and drug development. Discussions how to formulate, manufacture and regulate phage cocktails into successful phage therapies and gain valuable insights on the recent clinical advancements from industry leaders. Understand improved susceptibility testing and how CRISPR-based phage therapies can increase probability of success. This is exclusively an event for biopharma, clinicians and consumer product developers to harness the safety and efficacy of phages.
Who will be at the 5th Bacteriophage Therapy Summit?
Over 20 speakers and key global leaders from both the US and Europe will be attending.
The summit will bring together individuals in positions and occupations of; Presidents, VPs, Scientists, Investigators, C-Level, Professors, and Associate Professors. Those who work in a diversity of fields such as; drug development, research, NFP, academia, service providers, and consumer brands.
Agenda for the 5th Bacteriophage Therapy Summit 2023
Tuesday 21st February 2023
Identifying & Understanding Commercial Opportunity for Phage-Application Beyond Human Health
Joël van Mierlo R&D Manager Manager at Micreos Food Safety – Development & Application of Bacteriophage Products to Control Pathogens in the Food Industry
Matthew Tebeau COO at Proteon Pharmaceuticals – Taking Usage of Phage Therapy to Tackle Antibacterial Resistance in Aquaculture
Justyna Kowalska Head of Product Management at Proteon Pharmaceuticals – Exploring Advances of Phage Therapy in the Poultry Industry for Successful Regulatory Approval
Viviana Clavijo Chief Executive Director at SciPhage – Discussing Opportunities in the Development of Phage Cocktails for Animal Health
Articulating the Unending Possibilities of Phage Products, Phage Lysins & Modified Phages to Eradicate the Challenges of Resistance & Formulation
Vincent Fischetti Professor at The Rockefeller University – Exploring the Development of Phage Lysins for Bacteria Amidst the Urgency to Solve Antibiotic Resistance
Jakob Krause Haaber Vice President & Head of CRISPR & Delivery Technologies at SNIPR Biome – Unveiling the Process of Transforming Antimicrobial Therapy Through CRISPR-assisted Engineering of Phages
Michele Wales Chief Legal Officer at Adaptive Phage Therapeutics – Discussing the Consequences of Uncertain Bacteriophage Patentability on Phage Innovation in the United States
Tiina Orasmae Founder & Director at Meder Beauty – Phages for Faces: Chemical-Free Solutions for the Cosmetics Industry
Wednesday 22nd February 2023
Edward Burd Senior Vice President Regulatory Affairs at Biomx – Phage Therapy Regulation: From Night to Dawn
Jomana F. Musmar Senior Public Health Advisor and Executive Director at the US Department of Health and Human Services & Presidential at Advisory Council Combating Antibiotic Resistant Bacteria (PACCARB) – Discussing the US Efforts to Combat Resistance, & in particular, Work of the Federal Advisory Committee, the PACCARB, & its impact on AMR Policy
Mark Connelly Clinical Reviewer at the FDA – FDA Perspective: Regulatory Requirements to Commercialize Phages
Edward Burd Senior Vice President Regulatory Affairs at Biomx, Mark Connelly Clinical Reviewer at the FDA, and Jomana F. Musmar Senior Public Health Advisor and Executive Director at the US Department of Health and Human Services & Presidential at Advisory Council Combating Antibiotic Resistant Bacteria (PACCARB) – Comparing the Regulatory Requirements for Phage Commercialization: FDA vs Biotech vs Pharma
Bob Blasdel Research Director at Vésale Pharma – Phage Diagnostics: What’s New & How Does it Work?
Matjaz Peterka CEO at COBIK – Applications of Bacteriophages in Biosensors & Instrumentation
Nancy Tawil Chief Scientific Officer at PhageLux, Clara Leandro Head of Infection at TechnoPhage, and Vincent Fischetti Professor at The Rockefeller University – Brainstorming Essential Clinical Considerations for Efficient Trial Execution & Approval
Joseph Campbell Research Resources Project Officer of NIAID at NIH – NIAID Support for the Development of Phage Therapy
David Harper CEO at Evolution Biotech – Discussing the Selection of Disease Targets for Bacteriophages
Danish Malik Reader in Industrial Biotechnology at University of Loughborough – Using Advanced Metrology Tools to Evaluate Phage Aggregation in Liquid Formulations
Thursday 23rd February 2023
Nancy Tawil Chief Scientific Officer at PhageLux – Phage Therapy for the Prevention & Treatment of Pressure Ulcers: Safety & Efficacy of BACTELIDE in Conjunction with Standard of Care (SOC) Versus a Placebo
Iddo Nadav Weiner Senior Director & Head of Data Science at BiomX – Testing the Safety & Tolerability of BiomX’s Bacteriophage Therapy in Pseudomonas Aeruginosa Infections: A Cystic Fibrosis Phase 1b/2a Clinical Trial Study
Panagiota V. Tzani-Tzanopoulou Medical Science Liaison in Allergy and Clinical Immunology Unit at P&A Kyriakou Hospital – Targeting Dysbiotic Bacteria with Bacteriophages: New Insights into the Pathophysiology of Asthma
Clara Leandro Head of Infection at TechnoPhage – Bacteriophage Therapy in Patients with Chronic Urinary Tract Infections
David Harper CEO at Evolution Biotechnologies, Lorenzo Corsini Managing Director at BioNTech R&D, and Minmin Yen Co-Founder & CEO at PhagePro – Overcoming Barriers in Securing Funding & Questioning the Investment Process… Worth Billions or Nothing?
Lorenzo Corsini Managing Director at BioNTech R&D – Preclinical Data on the Gardnerella-Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance
Minmin Yen Co-Founder & CEO at PhagePro – Phages for All: How to Establish a Sustainable Phage Therapy Infrastructure in Resource-Constrained Conditions
View past events by Hanson Wade